Evidence Table 103. KQ 3—Continuous Glomeluar filtration rate

| **Author Year**  **Study Design** | **CHD Risk Category** | **CVD drug** | **CVD Dose (mg/d)** | **Supplement/ Control** | **N** | **Definition of outcome / Unit of outcome** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change/% change from baseline/**  **SD/**  **P Value** | **Between group differences in Means/ medians**  **SD/**  **P Value** | **Additional Comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ferraro 200922  Parallel | Unclear | Ramipril | 10 | Omega-3 | 15 | Estimated GFR  Unit: ml/min | Mean: 93.9  SD: 35.4 | NR | NR | N/A | Medium |
| No Treatment | 15 | Mean:67.7  SD: 35.0 | NR |